|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Van Poppel H, Roobol MJ, Chapple CR, Catto
JWF, N'Dow J, Sønksen J, Stenzl A and Wirth M: Prostate-specific
antigen testing as part of a risk-adapted early detection strategy
for prostate cancer: European association of urology position and
recommendations for 2021. Eur Urol. 80:703–711. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gudmundsson J, Sigurdsson JK,
Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA,
Gudjonsson SA, Gudbjartsson DF, Masson G, Frigge ML, et al:
Genome-wide associations for benign prostatic hyperplasia reveal a
genetic correlation with serum levels of PSA. Nat Commun.
9(4568)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lokant MT and Naz RK: Presence of PSA
auto-antibodies in men with prostate abnormalities (prostate
cancer/benign prostatic hyperplasia/prostatitis). Andrologia.
47:328–332. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Buddingh KT, Maatje MGF, Putter H, Kropman
RF and Pelger RCM: Do antibiotics decrease prostate-specific
antigen levels and reduce the need for prostate biopsy in type IV
prostatitis? A systematic literature review. Can Urol Assoc J.
12:E25–E30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhao Y, Zhang Y, Wang X, Lin D and Chen Z:
Relationship between body mass index and concentrations of prostate
specific antigen: A cross-sectional study. Scand J Clin Lab Invest.
80:162–167. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tan GH, Nason G, Ajib K, Woon DTS,
Herrera-Caceres J, Alhunaidi O and Perlis N: Smarter screening for
prostate cancer. World J Urol. 37:991–999. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Misra-Hebert AD, Hu B, Klein EA,
Stephenson A, Taksler GB, Kattan MW and Rothberg MB: Prostate
cancer screening practices in a large, integrated health system:
2007-2014. BJU Int. 120:257–264. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zaffaroni M, Vincini MG, Corrao G,
Lorubbio C, Repetti I, Mastroleo F, Putzu C, Villa R, Netti S,
D'Ecclesiis O, et al: Investigating nutritional and inflammatory
status as predictive biomarkers in oligoreccurent prostate cancer-A
RADIOSA trial preliminary analysis. Nutrients.
15(4583)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jurisic V: Multiomic analysis of cytokines
in immuno-oncology. Expert Rev Proteomics. 17:663–674.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tang Z, Li S, Zeng M, Zeng L and Tang Z:
The association between systemic immune-inflammation index and
prostate-specific antigen: Results from NHANES 2003-2010. PLoS One.
19(e0313080)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Beer TM, Lalani AS, Lee S, Mori M, Eilers
KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, et al:
C-reactive protein as a prognostic marker for men with
androgen-independent prostate cancer: results from the ASCENT
trial. Cancer. 112:2377–2383. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liao DW, Hu X, Wang Y, Yang ZQ and Li X:
C-reactive protein is a predictor of prognosis of prostate cancer:
A systematic review and meta-analysis. Ann Clin Lab Sci.
50:161–171. 2020.PubMed/NCBI
|
|
14
|
Rajwa P, Schuettfort VM, D'Andrea D, Quhal
F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS,
Mostafaei H, et al: Impact of systemic Immune-inflammation Index on
oncologic outcomes in patients treated with radical prostatectomy
for clinically nonmetastatic prostate cancer. Urol Oncol. 39:785
e19–785 e27. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jurisic V, Terzic T, Colic S and Jurisic
M: The concentration of TNF-alpha correlate with number of
inflammatory cells and degree of vascularization in radicular
cysts. Oral Dis. 14:600–605. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cui S, Cao S, Chen Q, He Q and Lang R:
Preoperative systemic inflammatory response index predicts the
prognosis of patients with hepatocellular carcinoma after liver
transplantation. Front Immunol. 14(1118053)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sawada R, Akiyoshi T, Kitagawa Y, Hiyoshi
Y, Mukai T, Nagasaki T, Yamaguchi T, Konishi T, Yamamoto N, Ueno M
and Fukunaga Y: Systemic inflammatory markers combined with
tumor-infiltrating lymphocyte density for the improved prediction
of response to neoadjuvant chemoradiotherapy in rectal cancer. Ann
Surg Oncol. 28:6189–6198. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sun Z, Ju Y, Han F, Sun X and Wang F:
Clinical implications of pretreatment inflammatory biomarkers as
independent prognostic indicators in prostate cancer. J Clin Lab
Anal. 32(e22277)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lin HY, Zhu X, Aucoin AJ, Fu Q, Park JY
and Tseng TS: Dietary and serum antioxidants associated with
prostate-specific antigen for middle-aged and older men. Nutrients.
15(3298)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Song J, Chen C, He S, Chen W, Su J, Yuan
D, Sun F and Zhu J: Is there a non-linear relationship between
dietary protein intake and prostate-specific antigen: Proof from
the national health and nutrition examination survey (2003-2010).
Lipids Health Dis. 19(82)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu K, Yan Y, Cheng C, Li S, Liao Y, Zeng
J, Chen Z and Zhou J: The relationship between serum albumin and
prostate-specific antigen: A analysis of the National Health and
Nutrition Examination Survey, 2003-2010. Front Public Health.
11(1078280)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fan L, Chi C, Guo S, Wang Y, Cai W, Shao
X, Xu F, Pan J, Zhu Y, Shangguan X, et al: Serum pre-albumin
predicts the clinical outcome in metastatic castration-resistant
prostate cancer patients treated with abiraterone. J Cancer.
8:3448–3455. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Stikbakke E, Richardsen E, Knutsen T,
Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS and
Thune I: Inflammatory serum markers and risk and severity of
prostate cancer: The PROCA-life study. Int J Cancer. 147:84–92.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rulando M, Siregar GP and Warli SM:
Correlation between neutrophil-to-lymphocyte ratio with Gleason
score in patients with prostate cancer at Adam Malik Hospital Medan
2013-2015. Urol Ann. 13:53–55. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Müller L, Hahn F, Mähringer-Kunz A, Stoehr
F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler
J, et al: Immunonutritive scoring for patients with hepatocellular
carcinoma undergoing transarterial chemoembolization: Evaluation of
the CALLY Index. Cancers (Basel). 13(5018)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hashimoto I, Tanabe M, Onuma S, Morita J,
Nagasawa S, Maezawa Y, Kanematsu K, Aoyama T, Yamada T, Yukawa N,
et al: Clinical impact of the C-reactive protein-albumin-lymphocyte
index in post-gastrectomy patients with gastric cancer. In Vivo.
38:911–916. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu XY, Zhang X, Zhang Q, Ruan GT, Liu T,
Xie HL, Ge YZ, Song MM, Deng L and Shi HP: The value of
CRP-albumin-lymphocyte index (CALLY index) as a prognostic
biomarker in patients with non-small cell lung cancer. Support Care
Cancer. 31(533)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Takeda Y, Sugano H, Okamoto A, Nakano T,
Shimoyama Y, Takada N, Imaizumi Y, Ohkuma M, Kosuge M and Eto K:
Prognostic usefulness of the C-reactive protein-albumin-lymphocyte
(CALLY) index as a novel biomarker in patients undergoing
colorectal cancer surgery. Asian J Surg. 47:3492–3498.
2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Iida H, Tani M, Komeda K, Nomi T,
Matsushima H, Tanaka S, Ueno M, Nakai T, Maehira H, Mori H, et al:
Superiority of CRP-albumin-lymphocyte index (CALLY index) as a
non-invasive prognostic biomarker after hepatectomy for
hepatocellular carcinoma. HPB (Oxford). 24:101–115. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nazzal Z, Khatib B, Al-Quqa B, Abu-Taha L
and Jaradat A: The prevalence and risk factors of urinary
incontinence among women with type 2 diabetes in the North West
Bank: A cross-sectional study. Lancet. 398 (Suppl
1)(S42)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Laffin RJ, Chan DW, Tanasijevic MJ,
Fischer GA, Markus W, Miller J, Matarrese P, Sokoll LJ, Bruzek DJ,
Eneman J, et al: Hybritech total and free prostate-specific antigen
assays developed for the Beckman Coulter access automated
chemiluminescent immunoassay system: A multicenter evaluation of
analytical performance. Clin Chem. 47:129–132. 2001.PubMed/NCBI
|
|
32
|
Gao S, Li S, Wu B, Wang J, Ding S and Tang
Z: Relationship between albumin-globulin ratio and
prostate-specific antigen: A cross-sectional study based on NHANES
2003-2010. BMC Urol. 25(3)2025.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang W, Gu J, Liu Y, Liu X, Jiang L, Wu C
and Liu J: Pre-treatment CRP-albumin-lymphocyte index (CALLY Index)
as a prognostic biomarker of survival in patients with epithelial
ovarian cancer. Cancer Manag Res. 14:2803–2812. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cheng H, Ma J, Zhao F, Liu Y, Wu J, Wu T,
Li H, Zhang B, Liu H, Fu J, et al: IINS Vs CALLY index: A battle of
prognostic value in NSCLC patients following surgery. J Inflamm
Res. 18:493–503. 2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang H, Shi J, Xie H, Liu X, Ruan G, Lin
S, Ge Y, Liu C, Chen Y, Zheng X, et al: Superiority of
CRP-albumin-lymphocyte index as a prognostic biomarker for patients
with gastric cancer. Nutrition. 116(112191)2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ma R, Okugawa Y, Shimura T, Yamashita S,
Sato Y, Yin C, Uratani R, Kitajima T, Imaoka H, Kawamura M, et al:
Clinical implications of C-reactive protein-albumin-lymphocyte
(CALLY) index in patients with esophageal cancer. Surg Oncol.
53(102044)2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhuang J, Wang S, Wang Y, Wu Y and Hu R:
Prognostic value of CRP-Albumin-lymphocyte (CALLY) index in
patients undergoing surgery for breast cancer. Int J Gen Med.
17:997–1005. 2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hirata H, Fujii N, Oka S, Nakamura K,
Shimizu K, Kobayashi K, Hiroyoshi T, Isoyama N and Shiraishi K:
C-reactive protein-albumin-lymphocyte index as a novel biomarker
for progression in patients undergoing surgery for renal cancer.
Cancer Diagn Progn. 4:748–753. 2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhu D, Lin YD, Yao YZ, Qi XJ, Qian K and
Lin LZ: Negative association of C-reactive
protein-albumin-lymphocyte index (CALLY index) with all-cause and
cause-specific mortality in patients with cancer: Results from
NHANES 1999-2018. BMC Cancer. 24(1499)2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jurisic V, Radenkovic S and Konjevic G:
The actual role of LDH as tumor marker, biochemical and clinical
aspects. Adv Exp Med Biol. 867:115–124. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Graff JN, Beer TM, Liu B, Sonpavde G and
Taioli E: Pooled analysis of C-reactive protein levels and
mortality in prostate cancer patients. Clin Genitourin Cancer.
13:e217–e221. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Naik G, Morgan C, Rocha P, Templeton A,
Pond G and Sonpavde G: Prognostic impact of C-reactive protein
(CRP) in metastatic prostate cancer (MPC): A systematic review and
meta-analysis. J Clin Oncol. 32(43)2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhou K, Li C, Chen T, Zhang X and Ma B:
C-reactive protein levels could be a prognosis predictor of
prostate cancer: A meta-analysis. Front Endocrinol (Lausanne).
14(1111277)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Santotoribio JD and Jimenez-Romero ME:
Serum biomarkers of inflammation for diagnosis of prostate cancer
in patients with nonspecific elevations of serum prostate specific
antigen levels. Transl Cancer Res. 8:273–278. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lehrer S, Diamond EJ, Mamkine B, Droller
MJ, Stone NN and Stock RG: C-reactive protein is significantly
associated with prostate-specific antigen and metastatic disease in
prostate cancer. BJU Int. 95:961–962. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Nepal SP, Nakasato T, Fukagai T, Ogawa Y,
Nakagami Y, Shichijo T, Morita J, Maeda Y, Oshinomi K, Unoki T, et
al: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios
alone or combined with prostate-specific antigen for the diagnosis
of prostate cancer and clinically significant prostate cancer.
Asian J Urol. 10:158–165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Yin X, Xiao Y, Li F, Qi S, Yin Z and Gao
J: Prognostic role of neutrophil-to-lymphocyte ratio in prostate
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 95(e2544)2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Salciccia S, Frisenda M, Bevilacqua G,
Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S,
Giorgino G, Rosati D, et al: Prognostic role of
platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in
patients with non-metastatic and metastatic prostate cancer: A
meta-analysis and systematic review. Asian J Urol. 11:191–207.
2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Yuksel OH, Urkmez A, Akan S, Yldirim C and
Verit A: Predictive value of the platelet-to-lymphocyte ratio in
diagnosis of prostate cancer. Asian Pac J Cancer Prev.
16:6407–6412. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kwon YS, Han CS, Yu JW, Kim S, Modi P,
Davis R, Park JH, Lee P, Ha YS, Kim WJ and Kim IY: Neutrophil and
lymphocyte counts as clinical markers for stratifying low-risk
prostate cancer. Clin Genitourin Cancer. 14:e1–e8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Xu MS, Xu JL, Gao X, Mo SJ, Xing JY, Liu
JH, Tian YZ and Fu XF: Clinical study of neutrophil-to-lymphocyte
ratio and platelet-to-lymphocyte ratio in
hypertriglyceridemia-induced acute pancreatitis and acute biliary
pancreatitis with persistent organ failure. World J Gastrointest
Surg. 16:1647–1659. 2024.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH,
Lu AL, Li HP, Yuan F, Wu SB, Guo JW, et al: The clinical value of
neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation
index (SII), platelet-to-lymphocyte ratio (PLR) and systemic
inflammation response index (SIRI) for predicting the occurrence
and severity of pneumonia in patients with intracerebral
hemorrhage. Front Immunol. 14(1115031)2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wu Y, Chen Y, Yang X, Chen L and Yang Y:
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte
ratio (PLR) were associated with disease activity in patients with
systemic lupus erythematosus. Int Immunopharmacol. 36:94–99.
2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wang T, Yang Z, Zhou B and Chen Y:
Relationship between NLR and PLR ratios and the occurrence and
prognosis of progressive hemorrhagic injury in patients with
traumatic brain injury. J Invest Surg. 38(2470453)2025.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Li X, Wang L, Liu M, Zhou H and Xu H:
Association between neutrophil-to-lymphocyte ratio and diabetic
kidney disease in type 2 diabetes mellitus patients: A
cross-sectional study. Front Endocrinol (Lausanne).
14(1285509)2024.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Matia-Garcia I, Vadillo E, Pelayo R,
Muñoz-Valle JF, García-Chagollán M, Loaeza-Loaeza J,
Vences-Velázquez A, Salgado-Goytia L, García-Arellano S and
Parra-Rojas I: Th1/Th2 balance in young subjects: relationship with
cytokine levels and metabolic profile. J Inflamm Res. 14:6587–6600.
2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhu J: T helper cell differentiation,
heterogeneity, and plasticity. Cold Spring Harb Perspect Biol.
10(a030338)2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Shapouri-Moghaddam A, Mohammadian S,
Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi
A, Afshari JT and Sahebkar A: Macrophage plasticity, polarization,
and function in health and disease. J Cell Physiol. 233:6425–6440.
2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
McNeel DG, Nguyen LD, Ellis WJ, Higano CS,
Lange PH and Disis ML: Naturally occurring prostate cancer
antigen-specific T cell responses of a Th1 phenotype can be
detected in patients with prostate cancer. Prostate. 47:222–229.
2001.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Guan H, Peng R, Fang F, Mao L, Chen Z,
Yang S, Dai C, Wu H, Wang C, Feng N, et al: Tumor-associated
macrophages promote prostate cancer progression via
exosome-mediated miR-95 transfer. J Cell Physiol. 235:9729–9742.
2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Garrido MM, Marta JC, Ribeiro RM, Pinheiro
LC, Holdenrieder S and Guimarães JT: Comparison of three assays for
total and free PSA using hybritech and WHO calibrations. In Vivo.
35:3431–3439. 2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Kort SA, Martens F, Vanpoucke H, van
Duijnhoven HL and Blankenstein MA: Comparison of 6 automated assays
for total and free prostate-specific antigen with special reference
to their reactivity toward the WHO 96/670 reference preparation.
Clin Chem. 52:1568–1574. 2006.PubMed/NCBI View Article : Google Scholar
|
